Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide.
Read the full article on WikipediaAcromegaly Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by a specialist practicing in a hospital who is either: (i) an endocrinologist, (ii) an oncologist; OR Must be treated by a medical practitioner working under the direct supervision of one of the above mentioned specialist types within a hospital setting. The condition must be active, AND Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre, AND The treatment must be after failure of other therapy including dopamine agonists; OR The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated, AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose), AND The treatment must cease if IGF1 is not lower after 3 months of treatment, AND The treatment must not be given concomitantly with PBS-subsidised pegvisomant. In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.
Functional carcinoid tumour Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by a specialist practicing in a hospital who is either: (i) an endocrinologist, (ii) an oncologist; OR Must be treated by a medical practitioner working under the direct supervision of one of the above mentioned specialist types within a hospital setting. The condition must be causing intractable symptoms, AND Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, AND Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate, AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.
Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET) Clinical criteria: The condition must be unresectable locally advanced disease or metastatic disease, AND The condition must be World Health Organisation (WHO) grade 1 or 2, AND The treatment must be either: (i) as monotherapy; (ii) in combination with cabozantinib. Population criteria: Patient must be at least 18 years of age. WHO grade 1 of GEP-NET is defined as a mitotic count (10HPF) of less than 2 and Ki-67 index (%) of less than or equal to 2. WHO grade 2 of GEP-NET is defined as a mitotic count (10HPF) of 2-20 and Ki-67 index (%) of 3-20.
“2 hours (immediate release)5 days (sustained release)”
Working under the parallel aged-care framework? Aged-care equivalent →